<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Intelligent Bio Solutions Inc. — News on 6ix</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc</link>
<description>Latest news and press releases for Intelligent Bio Solutions Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 13:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/intelligent-bio-solutions-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583b278dffbe2df0fccd2.webp</url>
<title>Intelligent Bio Solutions Inc.</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc</link>
</image>
<item>
<title>Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-initiates-validation-study-for-rapid-drug-screening-cartridge-targeting-70percent-faster-results</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-initiates-validation-study-for-rapid-drug-screening-cartridge-targeting-70percent-faster-results</guid>
<pubDate>Mon, 20 Apr 2026 13:15:00 GMT</pubDate>
<description>Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach $1.62 billion by 2030 NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of a validation study aimed at significantly</description>
</item>
<item>
<title>Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified</guid>
<pubDate>Fri, 17 Apr 2026 12:30:00 GMT</pubDate>
<description>INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submissionNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabiliti</description>
</item>
<item>
<title>Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510k-clinical-program-targeting-multi-billion-dollar-us-drug-screening-market-57</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510k-clinical-program-targeting-multi-billion-dollar-us-drug-screening-market-57</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k)</description>
</item>
<item>
<title>Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-strengthens-european-ip-portfolio-with-eighth-patent-grant</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-strengthens-european-ip-portfolio-with-eighth-patent-grant</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Patent strengthens competitive position in European drug screening market and reinforces Company&apos;s European intellectual property protection NEW YORK,</description>
</item>
<item>
<title>Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-successfully-manufactures-and-ships-first-readers-with-new-partner-accelerating-scale-and-driving-gross-margin-expansion-in-anticipation-of-planned-us-entry</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-successfully-manufactures-and-ships-first-readers-with-new-partner-accelerating-scale-and-driving-gross-margin-expansion-in-anticipation-of-planned-us-entry</guid>
<pubDate>Wed, 25 Feb 2026 13:45:00 GMT</pubDate>
<description>Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (G</description>
</item>
<item>
<title>Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-partners-with-bouygues-uk-part-of-multi-billion-dollar-global-construction-giant-bouygues-construction-for-uk-drug-testing-rollout</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-partners-with-bouygues-uk-part-of-multi-billion-dollar-global-construction-giant-bouygues-construction-for-uk-drug-testing-rollout</guid>
<pubDate>Tue, 24 Feb 2026 13:45:00 GMT</pubDate>
<description>Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technologyNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construct</description>
</item>
<item>
<title>Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-reports-record-133000287</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-reports-record-133000287</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on Jan</description>
</item>
<item>
<title>Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-expects-report-133000863</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-expects-report-133000863</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions</description>
</item>
<item>
<title>Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-initiates-additional-133000011</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-initiates-additional-133000011</guid>
<pubDate>Wed, 28 Jan 2026 13:30:00 GMT</pubDate>
<description>Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its</description>
</item>
<item>
<title>Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-closing-220000241</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-closing-220000241</guid>
<pubDate>Fri, 02 Jan 2026 22:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggreg</description>
</item>
<item>
<title>Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-10-222000865</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-10-222000865</guid>
<pubDate>Wed, 31 Dec 2025 22:20:00 GMT</pubDate>
<description>NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants t</description>
</item>
<item>
<title>Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-manufacturing-134500629</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-manufacturing-134500629</guid>
<pubDate>Wed, 31 Dec 2025 13:45:00 GMT</pubDate>
<description>Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entryNEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rap</description>
</item>
<item>
<title>Intelligent Bio Solutions Announces Strategic Partnership with Vlepis, Provider of Advanced Sensing and Wearable Patch Technologies, to Drive Innovation in Non-Invasive Screening and Consumer Health Monitoring</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-strategic-133000964</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-strategic-133000964</guid>
<pubDate>Thu, 18 Dec 2025 13:30:00 GMT</pubDate>
<description>Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies Alliance positions INBS to enter the fast-growing consumer health market, broadening revenue opportunities beyond commercial screening NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive tes</description>
</item>
<item>
<title>Intelligent Bio Solutions Inc. Announces Reverse Stock Split</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-inc-announces-153000579</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-inc-announces-153000579</guid>
<pubDate>Fri, 12 Dec 2025 15:30:00 GMT</pubDate>
<description>NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025. Trading of the Company's common stock on The Nasdaq Capital Market (“Nasdaq”) will continue, on a split-adjusted</description>
</item>
<item>
<title>Intelligent Bio Solutions to Participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 2-3, 2025</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-to-participate-in-noble-capital-markets-21st-annual-emerging-growth-equity-conference-on-december-2-3-2025</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-to-participate-in-noble-capital-markets-21st-annual-emerging-growth-equity-conference-on-december-2-3-2025</guid>
<pubDate>Thu, 20 Nov 2025 13:30:00 GMT</pubDate>
<description>NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida. Conference DetailsDate: December 2–3, 2025Location: Florida Atlantic University, Boca Raton, FL Pr</description>
</item>
<item>
<title>Intelligent Bio Solutions to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-participate-noble-133000625</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-participate-noble-133000625</guid>
<pubDate>Thu, 20 Nov 2025 13:30:00 GMT</pubDate>
<description>New York, New York--(Newsfile Corp. - November 20, 2025) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida.Conference DetailsDate: December 2-3, 2025Location: Florida Atlantic University,...</description>
</item>
<item>
<title>Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-reports-fiscal-133000083</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-reports-fiscal-133000083</guid>
<pubDate>Wed, 12 Nov 2025 13:30:00 GMT</pubDate>
<description>Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company deliveri</description>
</item>
<item>
<title>Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-expects-report-133000891</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-expects-report-133000891</guid>
<pubDate>Tue, 04 Nov 2025 13:30:00 GMT</pubDate>
<description>Company Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and Reader Revenue Up Approximately 43% and 23% Year-Over-Year Respectively NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions,</description>
</item>
<item>
<title>Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-secures-33-123000956</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-secures-33-123000956</guid>
<pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same period the prior year. The continued growth brings the Company’s total number of active accounts to over 480,</description>
</item>
<item>
<title>Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider</title>
<link>https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-secures-major-123000002</link>
<guid isPermaLink="true">https://6ix.com/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-secures-major-123000002</guid>
<pubDate>Thu, 23 Oct 2025 12:30:00 GMT</pubDate>
<description>Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide Large new customer account highlights accelerating adoption of the Company's rapid, non-invasive drug testing technology across high-volume, safety-critical sectors NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today a</description>
</item>
</channel>
</rss>